Page 8 - ஐரோப்பிய சங்கம் க்கு தி படிப்பு ஆஃப் நீரிழிவு நோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article RALEIGH, N.C., April 15, 2021 /PRNewswire/  Precision Diabetes, Inc. (PDI), an emerging leader in precision diabetes diagnostics, announced results today from a study on its Precision IGT prediabetes test at the Precision Diabetes Medicine 2021 Conference, the annual research symposium of the Precision Medicine in Diabetes Initiative (PMDI) a joint effort of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). The study, Serum Alpha-Hydroxybutyrate (AHB) Predicts Elevated 1-Hour Glucose Levels in Normoglycemic Patients, was designed to assess the predictive value of AHB for impaired glucose tolerance as measured by the 1-hour oral glucose tolerance test (OGTT).  Utilizing a proprietary algorithm that incorporates AHB and predicts 1-hour glucose levels greater than 155 mg/dL, Precision IGT was strongly predictive of abnormalities in glucose regulation, even after controlling for known ris

United statesNorth carolinaJacqueline madejczykEuropean association for the study of diabetesTrue health liquidating trustPrecision medicine in diabetes initiativeAmerican diabetes associationTrue health diagnosticsPrecision diabetes incPrecision diabetesPrecision diabetes medicinePrecision medicineDiabetes initiativeEuropean associationPredicts elevatedHour glucose levels